The department will give Merck $23 million to produce V920 doses over the next year and will work with the drugmaker to help secure FDA approval for the vaccine.
The agency’s response comes as the Ebola virus continues to spread in Congo. It has killed at least 1,900 people in the last year.
As of Aug. 16, more than 192,000 people have been vaccinated with the experimental vaccine.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
